Shopping Cart

LAFEROBION® suppositories 10 in pack antiviral, antiproliferative and immunomodulating effect

LAFEROBION® suppositories 10 in pack  antiviral, antiproliferative and immunomodulating effect
Product Code :924
Availability :In Stock
  • $35.00

Free Shipping

Shipping time 12-14 days.

Ask a question

Laferobion - suppositories 10 in pack . One pack

Packaging  -10 suppositories in a blister pack. 1 blister pack with 2 blister packs with 5 suppositories in a cardboard box


Composition 1 suppository contains: interferon alpha-2b recombinant human — 150,000 IU or 500,000 IU


Age  Children from the very birth



LAFEROBION® suppositories 150,000 MO, suppositories 500,000 MO



for medical use of the drug




active substance: interferon alfa-2b


1 suppository contains: recombinant human interferon alfa-2b - 150,000 IU or 500,000 IU;


excipients: tocopherol acetate 5% butyric solution, ascorbic acid, solid fat.


Dosage form.



The main physico-chemical properties: suppositories bullet-shaped yellowish-white color with a homogeneous consistency.


Pharmacotherapeutic group.

Immunostimulants. Interferons. Interferon alfa-2b.


ATX code L03A B05.


Pharmacological properties.


antiviral, antiproliferative and immunomodulating effect.

Interferon alfa-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulating effect. The active substance of the drug Laferobion® - interferon alpha-2b recombinant has an immunomodulating effect on T and B lymphocytes, normalizes the content of immunoglobulin E, and has antiviral activity. Antibodies are not formed that neutralize the antiviral activity of recombinant interferon alpha-2b, even when used for 2 years, the functioning of the endogenous system is normalized.




The pharmacokinetic properties of recombinant interferon alfa-2b have been little studied.


Clinical characteristics


For children: in the complex treatment of acute respiratory viral infections (ARVI).



Hypersensitivity to the components of the drug; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi's sarcoma; severe cardiovascular disease; psoriasis, severe impaired liver and / or kidney function; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis with progressive or decompensated liver cirrhosis; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); a history of autoimmune hepatitis or other autoimmune diseases. Inhibition of the myeloid germ of hematopoiesis.

Write a review

Note: HTML is not translated!
    Bad           Good